4.7 Review

Peptide-based delivery to bone

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 64, Issue 12, Pages 1220-1238

Publisher

ELSEVIER
DOI: 10.1016/j.addr.2012.05.017

Keywords

RANKL (receptor activator of NF-kappa B ligand); Antagonist; Bone resorption inhibitory peptide; Bone formation stimulatory peptide; Cholesterol-bearing pullulan (CHP) nanogel; BMP; Collagen; Thrombin; Bone-targeting peptide; Half-life; Stability

Funding

  1. Ministry of Education, Culture, Sports, Science, and Technology of Japan [19390472, 23659867, 22-00432]
  2. Grants-in-Aid for Scientific Research [24390413, 23659867] Funding Source: KAKEN

Ask authors/readers for more resources

Peptides are attractive as novel therapeutic reagents, since they are flexible in adopting and mimicking the local structural features of proteins. Versatile capabilities to perform organic synthetic manipulations are another unique feature of peptides compared to protein-based medicines, such as antibodies. On the other hand, a disadvantage of using a peptide for a therapeutic purpose is its low stability and/or high level of aggregation. During the past two decades, numerous peptides were developed for the treatment of bone diseases, and some peptides have already been used for local applications to repair bone defects in the clinic. However, very few peptides have the ability to form bone themselves. We herein summarize the effects of the therapeutic peptides on bone loss and/or local bone defects, including the results from basic studies. We also herein describe some possible methods for overcoming the obstacles associated with using therapeutic peptide candidates. (C) 2012 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available